Sight Sciences (NASDAQ:SGHT) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Sight Sciences (NASDAQ:SGHT – Free Report) from a buy rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

A number of other brokerages have also commented on SGHT. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research note on Wednesday, November 4th. HC Wainwright initiated coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective on the stock. Citigroup upped their price target on Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, October 5th. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (up from $9.00) on shares of Sight Sciences in a research report on Thursday, November 5th. Finally, UBS Group upped their price target on Sight Sciences from $8.00 to $13.50 and gave the company a “buy” rating in a research report on Thursday, November 12th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.31.

Get Our Latest Analysis on Sight Sciences

Sight Sciences Stock Performance

Shares of SGHT stock opened at $10.59 on Friday. Sight Sciences has a fifty-two week low of $3.38 and a fifty-two week high of $11.60. The stock’s 50-day moving average is $9.01 and its two-hundred day moving average is $6.23. The company has a debt-to-equity ratio of 0.71, a current ratio of 5.04 and a quick ratio of 4.72. The firm has a market cap of $588.59 million, a P/E ratio of -20.37 and a beta of 2.44.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $24.92 million during the quarter, compared to analyst estimates of $23.55 million. Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%. Analysts predict that Sight Sciences will post -0.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Sight Sciences

In other news, CTO David Badawi sold 7,797 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $70,562.85. Following the transaction, the chief technology officer directly owned 1,975,075 shares in the company, valued at $17,874,428.75. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Brenton Taylor sold 2,988 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $8.85, for a total value of $26,443.80. Following the transaction, the executive vice president owned 261,990 shares in the company, valued at approximately $2,318,611.50. This trade represents a 1.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 47,646 shares of company stock valued at $429,157. 30.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently bought and sold shares of the company. Conquis Financial LLC acquired a new stake in shares of Sight Sciences during the second quarter worth about $27,000. The Manufacturers Life Insurance Company bought a new position in Sight Sciences during the 2nd quarter worth about $60,000. Ieq Capital LLC bought a new stake in shares of Sight Sciences in the second quarter worth $135,000. Hsbc Holdings PLC acquired a new stake in shares of Sight Sciences in the first quarter valued at about $147,000. Finally, Algert Global LLC increased its position in shares of Sight Sciences by 25.3% during the 2nd quarter. Algert Global LLC now owns 28,266 shares of the company’s stock worth $153,000 after purchasing an additional 5,706 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Further Reading

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.